TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00747123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-011
Description: ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-011
Description: ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-011
Description: ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by the subcutaneous route of administration monthly for 4 doses.
Study: NCT02475525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine enriched oral nutritional supplement
Description: oral nutritional supplement containing arginine
Study: NCT03093740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Based on negative viral resistance testing of the donor treatment will be Zepatier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier plus Sofosbuvir
Description: Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
Study: NCT03322774

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: digital Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment.
Study: NCT02400437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Doses given on Day 1 of induction and maintenance cycles.
Study: NCT03949088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF and Na profiling
Description: Modulation of UF and dialysate sodium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF and Na profiling
Description: Modulation of UF and dialysate sodium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF and Na profiling
Description: Modulation of UF and dialysate sodium
Study: NCT00994773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: daily doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: daily doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: daily doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir
Study: NCT01508013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appearance-Focused Website Intervention
Description: The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Website
Description: The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
Study: NCT00477477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
Study: NCT03675074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neujia
Description: Neujia devices endoscopically deployed for jejunoileal compression anastomosis
Study: NCT03939247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Tecaretherapy
Description: The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inactive Tecaretherapy
Description: Inactive Tecaretherapy: the device will not provide any current.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CPT
Description: Conventional physiotherapy treatment (massage, eccentric exercises, stretching)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPT
Description: Conventional physiotherapy treatment (massage, eccentric exercises, stretching)

Intervention type: OTHER
Group type: OTHER
Intervention: CPT
Description: Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
Study: NCT03428126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation.
Study: NCT02172456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-radiolabelled tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-radiolabelled tiotropium
Study: NCT04324294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUS enhanced with contrast to evaluate pancreas
Description: Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
Study: NCT04181840

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and faeces tests
Description: During V1 - Laboratory tests, particularly for calprotectin concentration assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance spectroscopy test
Description: During V1 - the electrical impedance of anal sphincter muscles will be measured

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Full gynecological and proctological examination
Description: During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transanal ultrasonography
Description: During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determining the degree of sphincter injury
Description: During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
Study: NCT01805817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN® (Drospirenone/Ethinyl Estradiol)
Description: oral contraceptive pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN® (Drospirenone/Ethinyl Estradiol)
Description: oral contraceptive pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN® (Drospirenone/Ethinyl Estradiol)
Description: oral contraceptive pills

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Copper-T is an intrauterine device (IUD)
Description: intrauterine device for contraception

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Copper-T is an intrauterine device (IUD)
Description: intrauterine device for contraception

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Copper-T is an intrauterine device (IUD)
Description: intrauterine device for contraception

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing system
Description: intrauterine device
Study: NCT00907517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV infusion
Study: NCT00733551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK962040
Description: GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
Study: NCT03322774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Hygiene Education Control
Description: Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
Study: NCT00733551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
Study: NCT03322774

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Hygiene Education Control
Description: Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
Study: NCT00733551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given orally, once daily, in the morning, in a fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given orally, once daily, in the morning, in a fasted state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
Study: NCT02186496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 8/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 8mg and Amlodipine 5mg
Study: NCT03134937

Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)
Description: Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
Study: NCT04402021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Walking
Description: Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.

Intervention type: OTHER
Group type: OTHER
Intervention: Quiet Rest
Description: The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
Study: NCT03696732

Intervention type: OTHER
Intervention: Anxiety questionnaire
Description: Spielberger. State-Trait Inventory questionnaire

Intervention type: OTHER
Intervention: VAS questionnaire
Description: verbal numerical scale (VNS) anxiety score
Study: NCT01405521

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine placebo (excipients only)
Description: single oral dose,

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ty21a
Description: 3 oral doses, alternate days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M10ZH09 vaccine
Description: single oral dose
Study: NCT00676429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as oral solution, individually titrated
Study: NCT03229356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices Advisory (BPA)
Description: 1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BPA + Enhanced Education
Description: BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
Study: NCT01745718

Intervention type: OTHER
Group type: OTHER
Intervention: Cytological imprints
Description: Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
Study: NCT01805817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing system
Description: intrauterine device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing system
Description: intrauterine device
Study: NCT02588651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: study drug given intravenously to determine efficacy in study diseases
Study: NCT04159415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose REGN4461
Description: IV infusion loading dose or SC injection QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose REGN4461
Description: IV infusion loading dose or SC injection QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose REGN4461
Description: IV infusion loading dose or SC injection QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose REGN4461
Description: IV infusion loading dose or SC injection QW.
Study: NCT03257852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5094
Description: intravenously administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy
Description: MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate therapy
Description: MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
Study: NCT03990571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO
Study: NCT04233567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given PO
Study: NCT01391195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy by low level laser therapy
Description: Phototherapy by low level laser therapy during 9 weeks
Study: NCT03677882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Body Bridging Group Session
Description: Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
Study: NCT02969031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced SCOPE training
Description: Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Communication training
Description: Standard Communication training
Study: NCT03572855

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Scoliosis Brace
Description: Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
Study: NCT02409303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen-Refer-Treat Intervention
Description: This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
Study: NCT03777865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: All subjects receive a single dose (0.5mL) of 13vPnC
Study: NCT02611830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg IV
Description: Vedolizumab intravenous infusion
Study: NCT02855359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denintuzumab mafodotin
Description: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denintuzumab mafodotin
Description: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
Study: NCT02611830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg IV
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg IV
Description: Vedolizumab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Vedolizumab intravenous infusion placebo
Study: NCT02855359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denintuzumab mafodotin
Description: SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT02611830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Vedolizumab intravenous infusion placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab 108 mg SC
Description: Vedolizumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Vedolizumab subcutaneous injection placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Vedolizumab subcutaneous injection placebo